FAQ on CNS Pharmaceuticals Inc.'s 1-for-12 Reverse Stock Split

What is CNS Pharmaceuticals Inc. announcing?

CNS Pharmaceuticals Inc. is announcing a 1-for-12 reverse stock split effective July 22, 2025, to consolidate shares and adjust warrants and equity awards proportionally.

Why is CNS Pharmaceuticals Inc. implementing a reverse stock split?

The reverse stock split is designed to affect all shareholders uniformly by consolidating shares, reducing the authorized share count to 25 million, and maintaining the par value at $0.001.

How will the reverse stock split work?

Each 12 shares of common stock will convert into one share, with proportional adjustments to warrants and equity awards, and no fractional shares will be issued—holders will receive cash instead.

When will the reverse stock split take effect?

The reverse stock split will take effect on July 22, 2025.

What will happen to the stock symbol and CUSIP number after the split?

The common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508.

Who is affected by this reverse stock split?

All shareholders of CNS Pharmaceuticals Inc. are affected uniformly by this reverse stock split.

What are the implications of this reverse stock split for shareholders?

Shareholders will see their shares consolidated, with adjustments to warrants and equity awards, and any fractional shares will be compensated with cash.

Where can I find more information about CNS Pharmaceuticals Inc.?

For more information, visit the company’s website at www.CNSPharma.com or the company’s newsroom at https://ibn.fm/CNSP.

What is CNS Pharmaceuticals Inc.’s focus?

CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

What is TinyGems?

TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN, providing extensive distribution and corporate communications solutions.